Results 71 to 80 of about 2,602 (175)

Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir

Case Reports in Gastroenterology, 2016
Daclatasvir (DCV) and asunaprevir (ASV) are direct-acting antivirals (DAAs) used in the treatment of chronic hepatitis C virus (HCV) infection. Combined therapy with DCV and ASV shows high efficacy and safety even in patients with cirrhosis.
Hayato Baba, Kazuto Tajiri, Kohei Nagata, Kengo Kawai, Masami Minemura, Toshiro Sugiyama   +5 more
doaj   +1 more source

Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients [PDF]

, 2017
Short communication[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated. Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and ...
Castro-Iglesias, Ángeles, Cid-Silva, Purificación, Delgado, Manuel, Margusino-Framiñán, Luis, Meijide, Héctor, Mena, Álvaro, Morano, Luis, Pedreira, José D., Pernas, Berta, Poveda, Eva, Rodríguez-Osorio, Iria, Suárez, Marta, Tabernilla, Andrés   +12 more
core   +2 more sources

Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy

Journal of Viral Hepatitis, Volume 32, Issue 4, April 2025.
ABSTRACT This multicentre study investigated the dynamics of thrombospondin 2 (TSP2) levels during direct‐acting antiviral (DAA) therapy in hepatitis C virus (HCV) infected patients and evaluated TSP2's potential as a predictive marker for hepatocellular carcinoma (HCC).
Takanobu Iwadare, Takefumi Kimura, Ayumi Sugiura, Taiki Okumura, Shun‐ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Tomoo Yamazaki, Satoru Joshita, Naoki Tanaka, Takeji Umemura   +10 more
wiley   +1 more source

Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions

Journal of the Formosan Medical Association, 2019
Background/Purpose: Treatment with daclatasvir plus asunaprevir (DCV + ASV) for 24 weeks provided a sustained virologic response (SVR) rate of over 90% in hepatitis C virus genotype 1b (HCV-1b) infected patients without non-structural 5A (NS5A ...
Ming-Lung Yu, Chao-Hung Hung, Yi-Hsiang Huang, Cheng-Yuan Peng, Chun-Yen Lin, Pin-Nan Cheng, Rong-Nan Chien, Shih-Jer Hsu, Chen-Hua Liu, Chung-Feng Huang, Chien-Wei Su, Jee-Fu Huang, Chun-Jen Liu, Jia-Horng Kao, Wan-Long Chuang, Pei-Jer Chen, Ding-Shinn Chen   +16 more
doaj   +1 more source

Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis [PDF]

, 2015
Short communication[Abstract] Objectives. The aim of the study was to establish the risk of liver toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving etravirine, according to the degree of liver fibrosis. Methods.
Bañón, S, Casado, José Luis, Castro-Iglesias, Ángeles, Mena, Álvaro, Moreno, A, Moreno, S, Pedreira, José D., Quereda, C   +7 more
core   +2 more sources

Engineering strategies to mitigate toxicities associated with CAR‐T cell therapy

BMEMat, Volume 3, Issue 1, March 2025.
This review provides a brief overview of several of the major, and potentially life‐threatening, toxicities associated with CAR T cell therapies and discusses various examples of the genetic and chemical engineering strategies employed to effectively mitigate such toxicities in preclinical models and clinical studies. Abstract Chimeric antigen receptor
Tyler Wolter, Yixin Wang, Quanyin Hu
wiley   +1 more source

Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C

Virology Journal, 2017
Background Direct-acting antivirals (DAAs) for chronic hepatitis C (CHC) treatment are tolerable and highly effective in a shorter period of time than before. However, resistance-associated variants (RAVs) can affect the efficacy of DAAs. The aim of this
Jung Hwan Yu, Jung Il Lee, Kwan Sik Lee, Ja Kyung Kim   +3 more
doaj   +1 more source

New Insights Into Hepatic Impairment (HI) Trials

Clinical and Translational Science, Volume 18, Issue 1, January 2025.
ABSTRACT Hepatic impairment (HI) trials are traditionally part of the clinical pharmacology development to assess the need for dose adaptation in people with impaired metabolic capacity due to their diseased liver. This review aimed at looking into the data from dedicated HI studies, cluster these data into various categories and connect the effect by ...
Sebastian Haertter, Maximilian Lobmeyer, Brian C. Ferslew, Pallabi Mitra, Thomas Arnhold   +4 more
wiley   +1 more source

Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy [PDF]

, 2014
Hepatitis C virus (HCV) infection represents an important public health problem worldwide. Reduction of HCV morbidity and mortality is a current challenge owned to several viral and host factors.
Carpio Pedroza, Juan Carlos, Cruz Rivera, Mayra, Escobar Gutierrez, Alejandro, Fonseca Coronado, Salvador, Martinez Guarneros, Armando, Preciado, María Victoria, Rahal, Paula, Ruiz Tovar, Karina, Valva, Pamela, Vazquez Chacon, Carlos, Yamasaki, Lilian   +10 more
core   +1 more source

Chemogenetic Tools in Focus: Proximity, Conformation, and Sterics

Chemistry–Methods, Volume 4, Issue 6, June 2024.
Chemogenetic tools have been widely applied to interrogate dynamic biological processes. They are genetically encoded systems that are controlled by user‐defined chemicals. In this review, chemogenetic tool designs for various biological applications are introduced and discussed.
Jiaqi Shen, Guanwei Zhou, Wenjing Wang
wiley   +1 more source